Literature DB >> 27492174

Myogenic Progenitors from Mouse Pluripotent Stem Cells for Muscle Regeneration.

Alessandro Magli1, Tania Incitti1, Rita C R Perlingeiro2.   

Abstract

Muscle homeostasis is maintained by resident stem cells which, in both pathologic and non-pathologic conditions, are able to repair or generate new muscle fibers. Although muscle stem cells have tremendous regenerative potential, their application in cell therapy protocols is prevented by several restrictions, including the limited ability to grow ex vivo. Since pluripotent stem cells have the unique potential to both self-renew and expand almost indefinitely, they have become an attractive source of progenitors for regenerative medicine studies. Our lab has demonstrated that embryonic stem cell (ES)-derived myogenic progenitors retain the ability to repair existing muscle fibers and contribute to the pool of resident stem cells. Because of their relevance in both cell therapy and disease modeling, in this chapter we describe the protocol to derive myogenic progenitors from murine ES cells followed by their intramuscular delivery in a murine muscular dystrophy model.

Entities:  

Keywords:  Cell therapy; ES and iPS cells; Muscle differentiation; Myogenic progenitors; Pax3; Pax7; Pluripotent; Skeletal muscle; Transplantation

Mesh:

Year:  2016        PMID: 27492174     DOI: 10.1007/978-1-4939-3810-0_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Myogenic progenitor specification from pluripotent stem cells.

Authors:  Alessandro Magli; Rita R C Perlingeiro
Journal:  Semin Cell Dev Biol       Date:  2017-12       Impact factor: 7.727

Review 2.  Skeletal Muscle Cell Induction from Pluripotent Stem Cells.

Authors:  Yusaku Kodaka; Gemachu Rabu; Atsushi Asakura
Journal:  Stem Cells Int       Date:  2017-04-26       Impact factor: 5.443

3.  Pluripotent stem cell-derived skeletal muscle fibers preferentially express myosin heavy-chain isoforms associated with slow and oxidative muscles.

Authors:  Tania Incitti; Alessandro Magli; Asher Jenkins; Karena Lin; Ami Yamamoto; Rita C R Perlingeiro
Journal:  Skelet Muscle       Date:  2020-06-03       Impact factor: 4.912

4.  Measuring sequencer size bias using REcount: a novel method for highly accurate Illumina sequencing-based quantification.

Authors:  Daryl M Gohl; Alessandro Magli; John Garbe; Aaron Becker; Darrell M Johnson; Shea Anderson; Benjamin Auch; Bradley Billstein; Elyse Froehling; Shana L McDevitt; Kenneth B Beckman
Journal:  Genome Biol       Date:  2019-04-29       Impact factor: 13.583

5.  Pax3 cooperates with Ldb1 to direct local chromosome architecture during myogenic lineage specification.

Authors:  Alessandro Magli; June Baik; Pruthvi Pota; Carolina Ortiz Cordero; Il-Youp Kwak; Daniel J Garry; Paul E Love; Brian D Dynlacht; Rita C R Perlingeiro
Journal:  Nat Commun       Date:  2019-05-24       Impact factor: 14.919

6.  Transplantation studies reveal internuclear transfer of toxic RNA in engrafted muscles of myotonic dystrophy 1 mice.

Authors:  Ricardo Mondragon-Gonzalez; Karim Azzag; Sridhar Selvaraj; Ami Yamamoto; Rita C R Perlingeiro
Journal:  EBioMedicine       Date:  2019-08-21       Impact factor: 11.205

7.  Time-dependent Pax3-mediated chromatin remodeling and cooperation with Six4 and Tead2 specify the skeletal myogenic lineage in developing mesoderm.

Authors:  Alessandro Magli; June Baik; Lauren J Mills; Il-Youp Kwak; Bridget S Dillon; Ricardo Mondragon Gonzalez; David A Stafford; Scott A Swanson; Ron Stewart; James A Thomson; Daniel J Garry; Brian D Dynlacht; Rita C R Perlingeiro
Journal:  PLoS Biol       Date:  2019-02-26       Impact factor: 9.593

8.  Muscle progenitor specification and myogenic differentiation are associated with changes in chromatin topology.

Authors:  Nan Zhang; Julen Mendieta-Esteban; Alessandro Magli; Karin C Lilja; Rita C R Perlingeiro; Marc A Marti-Renom; Aristotelis Tsirigos; Brian David Dynlacht
Journal:  Nat Commun       Date:  2020-12-04       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.